[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

VTGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.16%

Insider Buying (Last 12 Months): $17,958,751.40

Insider Selling (Last 12 Months): $0.00

Vistagen Therapeutics Insider Trading History Chart

Vistagen Therapeutics Share Price & Price History

^$3.72

▼ -0.04 (-1.06%)

As of 11/28/2023 01:00 AM ET

Days: 30 | 90 | 365

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

Vistagen Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2023	Commodore Capital Lp	Major Shareholder	Buy	775,756	$23.15	$17,958,751.40	1,575,000
8/18/2022	Jerry B Gin	Director	Buy	3,333	$5.40	$17,998.20	3,333
8/17/2022	Reid G Adler	Insider	Buy	10,000	$5.10	$51,000.00	11,154
8/17/2022	Shawn Singh	CEO	Buy	20,000	$5.10	$102,000.00	20,874
7/12/2022	Venrock Healthcare Capital Par	Major Shareholder	Sell	2,000	$26.70	$53,400.00	687,909
9/7/2021	Jerrold Duane Dotson	CFO	Sell	1,000	$93.60	$93,600.00	2,426
8/17/2021	H. Ralph Snodgrass	Insider	Buy	125	$81.90	$10,237.50

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Vistagen Therapeutics (NASDAQ:VTGN)

27.21% of Vistagen Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vistagen Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	GSA Capital Partners LLP	46,782	$0.25M	0.0%	-76.5%	0.500%
11/14/2023	Schonfeld Strategic Advisors LLC	138,500	$0.73M	0.0%	N/A	1.480%
11/9/2023	Blair William & Co. IL	85,173	$0.45M	0.0%	N/A	0.910%
10/24/2023	Raymond James & Associates	10,000	$52K	0.0%	N/A	0.107%
10/23/2023	BML Capital Management LLC	100,000	$0.52M	0.5%	N/A	1.068%
8/15/2023	Y Intercept Hong Kong Ltd	47,696	$89K	0.0%	N/A	0.510%
8/15/2023	Goldman Sachs Group Inc.	57,316	$0.11M	0.0%	-41.3%	0.612%
8/15/2023	Citadel Advisors LLC	19,871	$37K	0.0%	+12.4%	0.212%
8/14/2023	State Street Corp	25,464	$48K	0.0%	-99.6%	0.272%
8/11/2023	BlackRock Inc.	105,006	$0.20M	0.0%	-99.2%	1.316%
8/11/2023	Geode Capital Management LLC	57,322	$0.11M	0.0%	-98.3%	0.718%
5/16/2023	State Street Corp	6,432,023	$0.80M	0.0%	+4.4%	2.933%
5/16/2023	Geode Capital Management LLC	3,449,805	$0.43M	0.0%	+5.4%	1.573%
5/15/2023	Two Sigma Investments LP	331,287	$41K	0.0%	-49.9%	0.151%
5/15/2023	Deutsche Bank AG	252,033	$32K	0.0%	+188.0%	0.115%
5/12/2023	BlackRock Inc.	13,202,454	$1.65M	0.0%	+7.6%	6.020%
4/13/2023	Allspring Global Investments Holdings LLC	212,443	$26K	0.0%	N/A	0.097%
4/11/2023	Henrickson Nauta Wealth Advisors Inc.	200,000	$25K	0.0%	N/A	0.091%
2/16/2023	Alliancebernstein L.P.	315,900	$33K	0.0%	+76.8%	0.144%
2/15/2023	Morgan Stanley	249,386	$26K	0.0%	+61.0%	0.114%
2/14/2023	Two Sigma Investments LP	660,977	$68K	0.0%	-21.9%	0.301%
2/13/2023	Geode Capital Management LLC	3,272,616	$0.34M	0.0%	-3.2%	1.492%
2/13/2023	GSA Capital Partners LLP	5,095,354	$0.53M	0.1%	-2.4%	2.323%
2/9/2023	MAI Capital Management	617,733	$64K	0.0%	-66.7%	0.299%
1/27/2023	GPS Wealth Strategies Group LLC	253,205	$25K	0.0%	+3,444.8%	0.122%
12/8/2022	Bank of New York Mellon Corp	579,081	$88K	0.0%	-18.9%	0.280%
11/15/2022	Alliancebernstein L.P.	178,700	$27K	0.0%	+439.9%	0.086%
11/15/2022	State Street Corp	5,632,066	$0.86M	0.0%	+44.6%	2.723%
11/15/2022	Two Sigma Advisers LP	234,400	$36K	0.0%	N/A	0.113%
11/15/2022	Two Sigma Investments LP	846,098	$0.13M	0.0%	+1,486.0%	0.409%
11/15/2022	Vanguard Group Inc.	4,735,633	$0.72M	0.0%	-52.5%	2.290%
11/15/2022	Bank of New York Mellon Corp	579,081	$88K	0.0%	-18.9%	0.280%
11/14/2022	Renaissance Technologies LLC	3,762,374	$0.57M	0.0%	+353.0%	1.819%
11/7/2022	Virtu Financial LLC	230,742	$35K	0.0%	N/A	0.112%
8/16/2022	Commodore Capital LP	13,049,079	$11.48M	2.4%	+29.2%	6.309%
8/15/2022	State Street Corp	3,895,398	$3.43M	0.0%	+7.9%	1.885%
8/15/2022	Acuta Capital Partners LLC	11,361,451	$10M	5.6%	-3.2%	5.498%
8/15/2022	Millennium Management LLC	872,959	$0.77M	0.0%	-29.6%	0.422%
8/13/2022	Renaissance Technologies LLC	830,612	$0.73M	0.0%	-29.5%	0.402%
8/12/2022	Dorsey & Whitney Trust CO LLC	150,000	$0.13M	0.0%	+100.0%	0.073%
8/12/2022	Franklin Resources Inc.	9,448,954	$8.32M	0.0%	-4.9%	4.573%
7/29/2022	Oak Family Advisors LLC	390,742	$0.34M	0.2%	+93.7%	0.189%
7/29/2022	SG Americas Securities LLC	29,443	$26K	0.0%	-75.3%	0.014%
7/27/2022	Assenagon Asset Management S.A.	360,475	$0.32M	0.0%	N/A	0.174%
7/20/2022	Exchange Traded Concepts LLC	29,136	$26K	0.0%	+337.9%	0.014%
7/19/2022	MAI Capital Management	2,661,398	$2.34M	0.0%	N/A	1.288%
7/7/2022	Epiq Partners LLC	1,301,350	$1.15M	0.7%	+12.1%	0.630%
6/7/2022	Bank of America Corp DE	155,077	$0.19M	0.0%	-71.0%	0.075%
5/17/2022	Mirabella Financial Services LLP	30,100	$37K	0.0%	N/A	0.015%
5/17/2022	Jane Street Group LLC	58,491	$73K	0.0%	N/A	0.028%
5/16/2022	California State Teachers Retirement System	82,887	$0.10M	0.0%	-22.2%	0.040%
5/16/2022	Goldman Sachs Group Inc.	655,782	$0.81M	0.0%	-45.0%	0.318%
5/16/2022	State Street Corp	3,609,840	$4.48M	0.0%	-58.0%	1.748%
5/16/2022	Ghost Tree Capital LLC	1,315,154	$1.63M	0.4%	-34.2%	0.637%
5/13/2022	Renaissance Technologies LLC	1,178,489	$1.46M	0.0%	N/A	0.571%
5/13/2022	Northern Trust Corp	1,635,003	$2.03M	0.0%	-16.3%	0.792%
5/13/2022	Charles Schwab Investment Management Inc.	553,201	$0.69M	0.0%	+14.0%	0.268%
5/13/2022	XTX Topco Ltd	91,566	$0.11M	0.0%	N/A	0.044%
5/12/2022	BlackRock Inc.	11,732,424	$14.55M	0.0%	-1.4%	5.681%
5/12/2022	Rhumbline Advisers	192,881	$0.24M	0.0%	+22.8%	0.093%
5/12/2022	MetLife Investment Management LLC	133,291	$0.17M	0.0%	+58.5%	0.065%
5/12/2022	HighTower Advisors LLC	162,078	$0.20M	0.0%	+19.1%	0.078%
5/11/2022	Bank of New York Mellon Corp	768,848	$0.95M	0.0%	-5.5%	0.372%
5/11/2022	Dorsey & Whitney Trust CO LLC	75,000	$93K	0.0%	+275.0%	0.036%
5/11/2022	JPMorgan Chase & Co.	91,139	$0.11M	0.0%	+21.4%	0.044%
5/11/2022	GSA Capital Partners LLP	73,969	$92K	0.0%	N/A	0.036%
5/10/2022	Nicholas Investment Partners LP	4,570,387	$5.67M	0.4%	+6.6%	2.213%
5/9/2022	Principal Financial Group Inc.	111,054	$0.14M	0.0%	-25.5%	0.054%
5/4/2022	Advisor Group Holdings Inc.	32,809	$41K	0.0%	-23.2%	0.016%
5/4/2022	ClariVest Asset Management LLC	252,700	$0.31M	0.0%	-12.3%	0.122%
5/3/2022	Oak Family Advisors LLC	201,727	$0.25M	0.1%	+9.3%	0.098%
4/29/2022	SG Americas Securities LLC	119,157	$0.15M	0.0%	+194.5%	0.058%
4/29/2022	Nisa Investment Advisors LLC	80,000	$99K	0.0%	N/A	0.039%
4/27/2022	Epiq Partners LLC	1,161,350	$1.44M	0.8%	+15.9%	0.562%
2/15/2022	Commodore Capital LP	8,464,999	$16.51M	3.8%	+65.2%	4.239%
2/14/2022	Parallax Volatility Advisers L.P.	94,941	$0.19M	0.0%	N/A	0.048%
2/11/2022	Eagle Asset Management Inc.	14,723	$30K	0.0%	N/A	0.007%
2/10/2022	Rafferty Asset Management LLC	490,295	$0.96M	0.0%	+98.8%	0.246%
2/9/2022	Principal Financial Group Inc.	149,035	$0.29M	0.0%	+299.9%	0.075%
2/8/2022	ProShare Advisors LLC	42,391	$82K	0.0%	+70.8%	0.021%
2/8/2022	Northern Trust Corp	1,954,286	$3.81M	0.0%	-2.2%	0.979%
2/7/2022	SG Americas Securities LLC	40,460	$79K	0.0%	-46.7%	0.020%
2/3/2022	Advisor Group Holdings Inc.	42,696	$83K	0.0%	+45.0%	0.021%
2/2/2022	New York State Common Retirement Fund	367,052	$0.72M	0.0%	+173.6%	0.184%
2/2/2022	Oak Family Advisors LLC	184,517	$0.36M	0.1%	+4.7%	0.092%
1/31/2022	CWM LLC	13,500	$26K	0.0%	N/A	0.007%
1/25/2022	Epiq Partners LLC	1,002,350	$1.96M	1.0%	+9.4%	0.502%
11/16/2021	Schonfeld Strategic Advisors LLC	422,500	$1.16M	0.0%	-31.1%	0.212%
11/16/2021	Two Sigma Advisers LP	1,109,500	$3.04M	0.0%	+75.8%	0.575%
11/16/2021	Two Sigma Investments LP	1,118,684	$3.07M	0.0%	-5.9%	0.580%
11/16/2021	Commodore Capital LP	5,123,509	$14.04M	3.7%	+53.8%	2.656%
11/15/2021	California State Teachers Retirement System	103,192	$0.28M	0.0%	-60.9%	0.053%
11/15/2021	Sphera Funds Management LTD.	3,824,938	$10.48M	0.9%	-6.3%	1.983%
11/15/2021	Zacks Investment Management	12,000	$33K	0.0%	N/A	0.006%
11/15/2021	HighVista Strategies LLC	438,239	$1.20M	0.8%	+42.2%	0.227%
11/15/2021	Franklin Resources Inc.	10,118,437	$27.73M	0.0%	+1.8%	5.245%
11/15/2021	GSA Capital Partners LLP	31,984	$88K	0.0%	N/A	0.017%
11/12/2021	The Manufacturers Life Insurance Company	103,727	$0.28M	0.0%	-6.1%	0.054%
11/12/2021	Geode Capital Management LLC	3,078,554	$8.44M	0.0%	+2.2%	1.596%
11/12/2021	EAM Global Investors LLC	634,743	$1.74M	0.4%	N/A	0.329%

Data available starting January 2016

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $3.72

$3.52

$3.73

50 Day Range

MA: $3.64

$2.57

$5.60

52 Week Range

Now: $3.72

$1.62

$24.71

Volume

302,128 shs

Average Volume

586,451 shs

Market Capitalization

$100.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Who are the company insiders with the largest holdings of Vistagen Therapeutics?: Vistagen Therapeutics' top insider shareholders include:
Commodore Capital Lp (Major Shareholder)
Venrock Healthcare Capital Par (Major Shareholder)
Shawn Singh (CEO)
Reid G Adler (Insider)
Jerry B Gin (Director)
Learn More about top insider investors at Vistagen Therapeutics.
Who are the major institutional investors of Vistagen Therapeutics?: Vistagen Therapeutics' top institutional investors include:
Schonfeld Strategic Advisors LLC — 1.48%
BML Capital Management LLC — 1.07%
Blair William & Co. IL — 0.91%
GSA Capital Partners LLP — 0.50%
Group One Trading L.P. — 0.00%
Raymond James & Associates — 0.11%
Learn More about top institutional investors of Vistagen Therapeutics stock.
Which major investors are selling Vistagen Therapeutics stock?: During the previous quarter, VTGN stock was sold by these institutional investors:
GSA Capital Partners LLP
Which major investors are buying Vistagen Therapeutics stock?: During the last quarter, VTGN stock was bought by institutional investors including:
Schonfeld Strategic Advisors LLC
BML Capital Management LLC
Blair William & Co. IL
Group One Trading L.P.
Raymond James & Associates
Simplex Trading LLC
In the last year, these company insiders have bought Vistagen Therapeutics stock:
Commodore Capital Lp (Major Shareholder)
Venrock Healthcare Capital Par (Major Shareholder)
Shawn Singh (CEO)
Reid G Adler (Insider)
Learn More investors buying Vistagen Therapeutics stock.

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

VTGN Insider Trading

Vistagen Therapeutics Insider Trading History Chart

Vistagen Therapeutics Share Price & Price History

Vistagen Therapeutics Insider Trading History

SEC Filings (Institutional Ownership Changes) for Vistagen Therapeutics (NASDAQ:VTGN)

Institutional Buying and Selling by Quarter

Vistagen Therapeutics Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Vistagen Therapeutics?

Who are the major institutional investors of Vistagen Therapeutics?

Which major investors are selling Vistagen Therapeutics stock?

Which major investors are buying Vistagen Therapeutics stock?